论文部分内容阅读
目的综合评价胸腺五肽联合替比夫定治疗慢性乙型肝炎(乙肝)的疗效。方法 52例慢性乙肝患者,根据给药的不同,将患者分为替比夫定组(对照组)以及替比夫定联合胸腺五肽治疗组(治疗组),每组26例,比较两组的治疗效果。结果治疗组显效18例(69.2%),有效6例(23.1%),无效2例(7.7%),总有效率为92.3%;对照组显效15例(57.7%),有效6例(23.1%),无效5例(19.2%),总有效率为80.8%,治疗组总有效率明显高于对照组(P<0.05)。结论胸腺五肽联合替比夫定治疗可明显提高慢性乙肝患者总有效率,值得临床应用推广。
Objective To evaluate the efficacy of thymopentin combined with telbivudine in the treatment of chronic hepatitis B (hepatitis B). Methods 52 cases of chronic hepatitis B patients were divided into telbivudine group (control group) and telbivudine combined thymopentin group (treatment group) Therapeutic effect. Results In the treatment group, 18 cases (69.2%) were effective, 6 (23.1%) were effective, 2 (7.7%) were ineffective and the total effective rate was 92.3% ), 5 cases (19.2%) were ineffective and the total effective rate was 80.8%. The total effective rate in the treatment group was significantly higher than that in the control group (P <0.05). Conclusion Thymopentin combined with telbivudine treatment can significantly improve the total effective rate of patients with chronic hepatitis B, it is worth promoting the clinical application.